{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T22:58:37Z","timestamp":1789340317625,"version":"build-2803163510"},"reference-count":148,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T00:00:00Z","timestamp":1689379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Hepatocellular carcinoma (HCC) is a common and aggressive cancer with a high mortality rate. The incidence of HCC is increasing worldwide, and the lack of effective screening programs often results in delayed diagnosis, making it a challenging disease to manage. Immunotherapy has emerged as a promising treatment option for different kinds of cancers, with the potential to stimulate the immune system to target cancer cells. However, the current immunotherapeutic approaches for HCC have shown limited efficacy. Since HCC arises within a complex tumour microenvironment (TME) characterized by the presence of various immune and stromal cell types, the understanding of this interaction is crucial for the identification of effective therapy. In this review, we highlight recent advances in our understanding of the TME of HCC and the immune cells involved in anti-tumour responses, including the identification of new possible targets for immunotherapy. We illustrate a possible classification of HCC based on the tumour immune infiltration and give evidence about the role of SerpinB3, a serine protease inhibitor involved in the regulation of the immune response in different cancers.<\/jats:p>","DOI":"10.3390\/cancers15143629","type":"journal-article","created":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T00:56:47Z","timestamp":1689555407000},"page":"3629","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Novel Molecular Targets for Immune Surveillance of Hepatocellular Carcinoma"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-1288-709X","authenticated-orcid":false,"given":"Pietro","family":"Guerra","sequence":"first","affiliation":[{"name":"Unit of Internal Medicine and Hepatology (UIMH), Department of Medicine (DIMED), University of Padova, 35122 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7958-1906","authenticated-orcid":false,"given":"Andrea","family":"Martini","sequence":"additional","affiliation":[{"name":"Unit of Internal Medicine and Hepatology (UIMH), Department of Medicine (DIMED), University of Padova, 35122 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2077-9202","authenticated-orcid":false,"given":"Patrizia","family":"Pontisso","sequence":"additional","affiliation":[{"name":"Unit of Internal Medicine and Hepatology (UIMH), Department of Medicine (DIMED), University of Padova, 35122 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Angeli","sequence":"additional","affiliation":[{"name":"Unit of Internal Medicine and Hepatology (UIMH), Department of Medicine (DIMED), University of Padova, 35122 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,15]]},"reference":[{"key":"ref_1","unstructured":"Global Burden of Disease Cancer Collaboration (2019). Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol., 5, 1749\u20131768."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/hep.32542","article-title":"NAFLD-related Hepatocellular Carcinoma: The Growing Challenge","volume":"77","author":"Shah","year":"2023","journal-title":"Hepatology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular Carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular Carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The Global Epidemiology of NAFLD and NASH in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Kogiso, T., and Tokushige, K. (2021). The Current View of Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma. Cancers, 13.","DOI":"10.3390\/cancers13030516"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global Epidemiology of NAFLD-Related HCC: Trends, Predictions, Risk Factors and Prevention","volume":"18","author":"Huang","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.14309\/ajg.0000000000002015","article-title":"Emerging Tools for Hepatocellular Carcinoma Surveillance","volume":"117","author":"Singal","year":"2022","journal-title":"Am. J. Gastroenterol."},{"key":"ref_9","unstructured":"European Association for the Study of the Liver (2018). EASL Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. J. Hepatol., 69, 182\u2013236."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jhep.2022.01.023","article-title":"HCC Surveillance Improves Early Detection, Curative Treatment Receipt, and Survival in Patients with Cirrhosis: A Meta-Analysis","volume":"77","author":"Singal","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC Strategy for Prognosis Prediction and Treatment Recommendation: The 2022 Update","volume":"76","author":"Reig","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Singal, A.G., Llovet, J.M., Yarchoan, M., Mehta, N., Heimbach, J.K., Dawson, L.A., Jou, J.H., Kulik, L.M., Agopian, V.G., and Marrero, J.A. (2023). AASLD Practice Guidance on Prevention, Diagnosis, and Treatment of Hepatocellular Carcinoma. Hepatology.","DOI":"10.1097\/HEP.0000000000000466"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"iv238","DOI":"10.1093\/annonc\/mdy308","article-title":"Hepatocellular Carcinoma: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"29","author":"Vogel","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","article-title":"Asia\u2013Pacific Clinical Practice Guidelines on the Management of Hepatocellular Carcinoma: A 2017 Update","volume":"11","author":"Omata","year":"2017","journal-title":"Hepatol. Int."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/s41419-019-2173-1","article-title":"Sanguinarine Inhibits Epithelial\u2013Mesenchymal Transition via Targeting HIF-1\u03b1\/TGF-\u03b2 Feed-Forward Loop in Hepatocellular Carcinoma","volume":"10","author":"Su","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2174\/1871520622666220831124321","article-title":"Molecular Mechanisms of Sanguinarine in Cancer Prevention and Treatment","volume":"23","author":"Ullah","year":"2023","journal-title":"Anticancer Agents Med. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1002\/hep.32447","article-title":"Emerging Immunotherapy for HCC: A Guide for Hepatologists","volume":"75","author":"Foerster","year":"2022","journal-title":"Hepatology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1200\/JCO.20.00808","article-title":"Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma","volume":"38","author":"Finn","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e204564","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"216038","DOI":"10.1016\/j.canlet.2022.216038","article-title":"Immune Checkpoint Inhibitor Resistance in Hepatocellular Carcinoma","volume":"555","author":"Wang","year":"2023","journal-title":"Cancer Lett."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41573-022-00493-5","article-title":"Adaptive Immune Resistance at the Tumour Site: Mechanisms and Therapeutic Opportunities","volume":"21","author":"Kim","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"100380","DOI":"10.1016\/j.esmoop.2021.100380","article-title":"Efficacy and Activity of PD-1 Blockade in Patients with Advanced Esophageal Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis with Focus on the Value of PD-L1 Combined Positive Score","volume":"7","author":"Leone","year":"2022","journal-title":"ESMO Open"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"170","DOI":"10.4132\/jptm.2022.04.25","article-title":"What\u2019s New in Breast Pathology 2022: WHO 5th Edition and Biomarker Updates","volume":"56","author":"Muller","year":"2022","journal-title":"J. Pathol. Transl. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.18.00149","article-title":"Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non\u2013Small-Cell Lung Cancer with PD-L1 Tumor Proportion Score of 50% or Greater","volume":"37","author":"Reck","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Abou-Alfa, G.K., Lau, G., Kudo, M., Chan, S.L., Kelley, R.K., Furuse, J., Sukeepaisarnjaroen, W., Kang, Y.-K., Van Dao, T., and De Toni, E.N. (2022). Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. NEJM Evid., 1.","DOI":"10.1056\/EVIDoa2100070"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/liv.15504","article-title":"Immunotherapy in Hepatocellular Carcinoma: How Does Underlying Liver Disease Influence Therapeutic Strategy and Outcomes?","volume":"43","author":"Roth","year":"2023","journal-title":"Liver Int."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated Efficacy and Safety Data from IMbrave150: Atezolizumab Plus Bevacizumab vs. Sorafenib for Unresectable Hepatocellular Carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"S869","DOI":"10.1016\/j.annonc.2022.07.838","article-title":"714P\u2014Impact of Viral Aetiology in the Phase 3 HIMALAYA Study of Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma","volume":"33","author":"Chan","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab As Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial","volume":"38","author":"Finn","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab Versus Sorafenib in Advanced Hepatocellular Carcinoma (CheckMate 459): A Randomised, Multicentre, Open-Label, Phase 3 Trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"S1401","DOI":"10.1016\/j.annonc.2022.08.031","article-title":"LBA34\u2014Primary Results from the Phase III LEAP-002 Study: Lenvatinib plus Pembrolizumab versus Lenvatinib as First-Line (1L) Therapy for Advanced Hepatocellular Carcinoma (AHCC)","volume":"33","author":"Finn","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH Limits Anti-Tumour Surveillance in Immunotherapy-Treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The Evolving Landscape of Biomarkers for Checkpoint Inhibitor Immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1053\/j.gastro.2022.09.005","article-title":"Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma","volume":"164","author":"Haber","year":"2023","journal-title":"Gastroenterology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/hep.26731","article-title":"Immunodominance and Functional Alterations of Tumor-Associated Antigen-Specific CD8+T-Cell Responses in Hepatocellular Carcinoma","volume":"59","author":"Flecken","year":"2013","journal-title":"Hepatology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2217\/imt-2020-0278","article-title":"Phase I Studies of Peptide Vaccine Cocktails Derived from GPC3, WDRPUH and NEIL3 for Advanced Hepatocellular Carcinoma","volume":"13","author":"Ikeda","year":"2021","journal-title":"Immunotherapy"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.7150\/jca.39972","article-title":"Glypican-3: A New Target for Diagnosis and Treatment of Hepatocellular Carcinoma","volume":"11","author":"Guo","year":"2020","journal-title":"J. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41575-021-00438-0","article-title":"Advances in Immunotherapy for Hepatocellular Carcinoma","volume":"18","author":"Sangro","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41568-020-0285-7","article-title":"The Immune Contexture and Immunoscore in Cancer Prognosis and Therapeutic Efficacy","volume":"20","author":"Bruni","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1038\/s41388-020-1249-9","article-title":"Immune-Based Therapies for Hepatocellular Carcinoma","volume":"39","author":"Pinato","year":"2020","journal-title":"Oncogene"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41423-020-00572-w","article-title":"Immunobiology and Immunotherapy of HCC: Spotlight on Innate and Innate-like Immune Cells","volume":"18","author":"Ruf","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Rochigneux, P., Chanez, B., De Rauglaudre, B., Mitry, E., Chabannon, C., and Gilabert, M. (2021). Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials. Cancers, 13.","DOI":"10.3390\/cancers13020271"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.3748\/wjg.v28.i27.3346","article-title":"Regulatory T Cells and Their Associated Factors in Hepatocellular Carcinoma Development and Therapy","volume":"28","author":"Zhang","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/cac2.12345","article-title":"Tumor-Associated Macrophages in Liver Cancer: From Mechanisms to Therapy","volume":"42","author":"Cheng","year":"2022","journal-title":"Cancer Commun."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1084\/jem.20061104","article-title":"Phosphodiesterase-5 Inhibition Augments Endogenous Antitumor Immunity by Reducing Myeloid-Derived Suppressor Cell Function","volume":"203","author":"Serafini","year":"2006","journal-title":"J. Exp. Med."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Jeng, L.-B., Liao, L.-Y., Shih, F.-Y., and Teng, C.-F. (2022). Dendritic-Cell-Vaccine-Based Immunotherapy for Hepatocellular Carcinoma: Clinical Trials and Recent Preclinical Studies. Cancers, 14.","DOI":"10.3390\/cancers14184380"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/gutjnl-2015-310514","article-title":"Targeting of Tumour-Infiltrating Macrophages via CCL2\/CCR2 Signalling as a Therapeutic Strategy against Hepatocellular Carcinoma","volume":"66","author":"Li","year":"2017","journal-title":"Gut"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa1912035","article-title":"Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality","volume":"382","author":"Simon","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Ali, E., Trailin, A., Ambrozkiewicz, F., Li\u0161ka, V., and Hemminki, K. (2022). Activated Hepatic Stellate Cells in Hepatocellular Carcinoma: Their Role as a Potential Target for Future Therapies. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232315292"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"690","DOI":"10.3389\/fimmu.2016.00690","article-title":"Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma","volume":"7","author":"Jiang","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e0022","DOI":"10.1097\/HC9.0000000000000022","article-title":"Human VH-Based Chimeric Antigen Receptor T Cells Targeting Glypican 3 Eliminate Tumors in Preclinical Models of HCC","volume":"7","author":"Kolluri","year":"2023","journal-title":"Hepatol. Commun."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.ymthe.2019.04.020","article-title":"Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma","volume":"27","author":"Wu","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and Biomarkers of Severe Cytokine Release Syndrome after CD19 Chimeric Antigen Receptor\u2013Modified T-Cell Therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2014.10.001","article-title":"Immunotherapy of HCC Metastases with Autologous T Cell Receptor Redirected T Cells, Targeting HBsAg in a Liver Transplant Patient","volume":"62","author":"Qasim","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/hep.31662","article-title":"Immunosuppressive Drug-Resistant Armored T-Cell Receptor T Cells for Immune Therapy of HCC in Liver Transplant Patients","volume":"74","author":"Hafezi","year":"2021","journal-title":"Hepatology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1007\/s12072-021-10250-2","article-title":"Immunotherapy of HBV-Related Advanced Hepatocellular Carcinoma with Short-Term HBV-Specific TCR Expressed T Cells: Results of Dose Escalation, Phase I Trial","volume":"15","author":"Meng","year":"2021","journal-title":"Hepatol. Int."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00262-016-1800-2","article-title":"TCR Gene-Modified T Cells Can Efficiently Treat Established Hepatitis C-Associated Hepatocellular Carcinoma Tumors","volume":"65","author":"Spear","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/hep.29844","article-title":"Identification of \u03b1-fetoprotein-specific T-cell Receptors for Hepatocellular Carcinoma Immunotherapy","volume":"68","author":"Zhu","year":"2018","journal-title":"Hepatology"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1002\/hep.30477","article-title":"Tuning T-Cell Receptor Affinity to Optimize Clinical Risk-Benefit When Targeting Alpha-Fetoprotein\u2013Positive Liver Cancer","volume":"69","author":"Docta","year":"2019","journal-title":"Hepatology"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Chen, K.-J., Lin, S.-Z., Zhou, L., Xie, H.-Y., Zhou, W.-H., Taki-Eldin, A., and Zheng, S.-S. (2011). Selective Recruitment of Regulatory T Cell through CCR6-CCL20 in Hepatocellular Carcinoma Fosters Tumor Progression and Predicts Poor Prognosis. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0024671"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1146\/annurev-immunol-020711-075043","article-title":"Induced CD4+Foxp3+Regulatory T Cells in Immune Tolerance","volume":"30","author":"Bilate","year":"2012","journal-title":"Annu. Rev. Immunol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s12967-021-02854-x","article-title":"The Roles and Mechanisms of Hypoxia in Liver Fibrosis","volume":"19","author":"Cai","year":"2021","journal-title":"J. Transl. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"26","DOI":"10.20517\/2394-5079.2018.27","article-title":"Hypoxic Microenvironment and Hepatocellular Carcinoma Treatment","volume":"4","author":"Lin","year":"2018","journal-title":"Hepatoma Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"C569","DOI":"10.1152\/ajpcell.00207.2015","article-title":"Hypoxia: A Key Player in Antitumor Immune Response. A Review in the Theme: Cellular Responses to Hypoxia","volume":"309","author":"Noman","year":"2015","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"75763","DOI":"10.18632\/oncotarget.12409","article-title":"Hypoxia-Induced CCL28 Promotes Recruitment of Regulatory T Cells and Tumor Growth in Liver Cancer","volume":"7","author":"Ren","year":"2016","journal-title":"Oncotarget"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/hep.32419","article-title":"Hypoxia-Driven Immunosuppression by Treg and Type-2 Conventional Dendritic Cells in HCC","volume":"76","author":"Suthen","year":"2022","journal-title":"Hepatology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"187204","DOI":"10.1155\/2013\/187204","article-title":"The Inflammatory Microenvironment in Hepatocellular Carcinoma: A Pivotal Role for Tumor-Associated Macrophages","volume":"2013","author":"Capece","year":"2013","journal-title":"BioMed Res. Int."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jhep.2014.10.029","article-title":"Alternatively Activated (M2) Macrophages Promote Tumour Growth and Invasiveness in Hepatocellular Carcinoma","volume":"62","author":"Yeung","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/hep.30593","article-title":"Blocking Triggering Receptor Expressed on Myeloid Cells-1-Positive Tumor-Associated Macrophages Induced by Hypoxia Reverses Immunosuppression and Anti-Programmed Cell Death Ligand 1 Resistance in Liver Cancer","volume":"70","author":"Wu","year":"2019","journal-title":"Hepatology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jhep.2023.01.011","article-title":"Identification of a Tumour Immune Barrier in the HCC Microenvironment That Determines the Efficacy of Immunotherapy","volume":"78","author":"Liu","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-Derived Suppressor Cells as Regulators of the Immune System","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1158\/0008-5472.CAN-12-3381","article-title":"Higher Frequencies of GARP+CTLA-4+Foxp3+ T Regulatory Cells and Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma Patients Are Associated with Impaired T-Cell Functionality","volume":"73","author":"Kalathil","year":"2013","journal-title":"Cancer Res"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s11010-020-03982-6","article-title":"Protective and Therapeutic Effects of Sildenafil and Tadalafil on Aflatoxin B1-Induced Hepatocellular Carcinoma","volume":"476","author":"Chhonker","year":"2021","journal-title":"Mol. Cell. Biochem."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e23100","DOI":"10.1002\/jbt.23100","article-title":"Repurposing PDE5 Inhibitor Tadalafil and Sildenafil as Anticancer Agent against Hepatocellular Carcinoma via Targeting Key Events of Glucose Metabolism and Multidrug Resistance","volume":"36","author":"Chhonker","year":"2022","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"166267","DOI":"10.1016\/j.bbadis.2021.166267","article-title":"Tadalafil Enhances the Therapeutic Efficacy of BET Inhibitors in Hepatocellular Carcinoma through Activating Hippo Pathway","volume":"1867","author":"Kong","year":"2021","journal-title":"Biochim. Biophys. Acta (BBA)-Mol. Basis Dis."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Zhong, M., Zhong, C., Cui, W., Wang, G., Zheng, G., Li, L., Zhang, J., Ren, R., Gao, H., and Wang, T. (2019). Induction of Tolerogenic Dendritic Cells by Activated TGF-\u03b2\/Akt\/Smad2 Signaling in RIG-I-Deficient Stemness-High Human Liver Cancer Cells. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5670-9"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/hep.26694","article-title":"Human CD14+CTLA-4+ Regulatory Dendritic Cells Suppress T-Cell Response by Cytotoxic T-Lymphocyte Antigen-4-Dependent IL-10 and Indoleamine-2,3-Dioxygenase Production in Hepatocellular Carcinoma","volume":"59","author":"Han","year":"2014","journal-title":"Hepatology"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/01.cji.0000171291.72039.e2","article-title":"Vaccination of Advanced Hepatocellular Carcinoma Patients with Tumor Lysate-Pulsed Dendritic Cells: A Clinical Trail","volume":"28","author":"Lee","year":"2005","journal-title":"J. Immunother."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/hep.22626","article-title":"A Phase II Study of Adoptive Immunotherapy Using Dendritic Cells Pulsed with Tumor Lysate in Patients with Hepatocellular Carcinoma","volume":"49","author":"Palmer","year":"2009","journal-title":"Hepatology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.3892\/ijo.2012.1626","article-title":"Phase I\/II Study of Immunotherapy Using Tumor Antigen-Pulsed Dendritic Cells in Patients with Hepatocellular Carcinoma","volume":"41","author":"Tada","year":"2012","journal-title":"Int. J. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00432-012-1298-8","article-title":"Immunotherapy by Autologous Dendritic Cell Vaccine in Patients with Advanced HCC","volume":"139","author":"Mogawer","year":"2013","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/jso.23897","article-title":"Phase I Trial of Active Specific Immunotherapy with Autologous Dendritic Cells Pulsed with Autologous Irradiated Tumor Stem Cells in Hepatitis B-Positive Patients with Hepatocellular Carcinoma","volume":"111","author":"Wang","year":"2015","journal-title":"J. Surg. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1038\/bjc.2015.430","article-title":"A Phase I\/IIa Study of Adjuvant Immunotherapy with Tumour Antigen-Pulsed Dendritic Cells in Patients with Hepatocellular Carcinoma","volume":"113","author":"Lee","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"5395","DOI":"10.3748\/wjg.v23.i29.5395","article-title":"Phase I Clinical Study of Personalized Peptide Vaccination Combined with Radiotherapy for Advanced Hepatocellular Carcinoma","volume":"23","author":"Shen","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1158\/1078-0432.CCR-18-2293","article-title":"Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies","volume":"25","author":"Harding","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1158\/2159-8290.CD-19-0074","article-title":"\u03b2-Catenin Activation Promotes Immune Escape and Resistance to Anti\u2013PD-1 Therapy in Hepatocellular Carcinoma","volume":"9","author":"Bresnahan","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2016.03.012","article-title":"Expansion and Activation of CD103+ Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition","volume":"44","author":"Salmon","year":"2016","journal-title":"Immunity"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1136\/gutjnl-2021-325918","article-title":"Inflamed and Non-Inflamed Classes of HCC: A Revised Immunogenomic Classification","volume":"72","author":"Montironi","year":"2023","journal-title":"Gut"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3389\/fimmu.2018.00635","article-title":"The Contribution of Non-Professional Antigen-Presenting Cells to Immunity and Tolerance in the Liver","volume":"9","author":"Mehrfeld","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1016\/j.exphem.2015.06.130","article-title":"Tissue-Resident Macrophages Originate from Yolk Sac-Derived Erythro-Myeloid Progenitors","volume":"43","author":"Perdiguero","year":"2015","journal-title":"Exp. Hematol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41575-018-0020-y","article-title":"Liver Sinusoidal Endothelial Cells\u2014Gatekeepers of Hepatic Immunity","volume":"15","author":"Shetty","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1046\/j.1365-2249.1998.00713.x","article-title":"IL-10 Down-Regulates T Cell Activation by Antigen-Presenting Liver Sinusoidal Endothelial Cells through Decreased Antigen Uptake via the Mannose Receptor and Lowered Surface Expression of Accessory Molecules","volume":"114","author":"Knolle","year":"1998","journal-title":"Clin. Exp. Immunol."},{"key":"ref_96","first-page":"G1310","article-title":"Hepatic Recruitment of Macrophages Promotes Nonalcoholic Steatohepatitis through CCR2","volume":"302","author":"Miura","year":"2012","journal-title":"Am. J. Physiol. Liver Physiol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.immuni.2020.06.003","article-title":"Impaired Kupffer Cell Self-Renewal Alters the Liver Response to Lipid Overload during Non-Alcoholic Steatohepatitis","volume":"53","author":"Tran","year":"2020","journal-title":"Immunity"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"105889","DOI":"10.1016\/j.cct.2019.105889","article-title":"A Randomized, Double-Blind, Multicenter, Phase 2b Study to Evaluate the Safety and Efficacy of a Combination of Tropifexor and Cenicriviroc in Patients with Nonalcoholic Steatohepatitis and Liver Fibrosis: Study Design of the TANDEM Trial","volume":"88","author":"Pedrosa","year":"2020","journal-title":"Contemp. Clin. Trials"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/hep.29544","article-title":"Therapeutic Inhibition of Inflammatory Monocyte Recruitment Reduces Steatohepatitis and Liver Fibrosis","volume":"67","author":"Krenkel","year":"2018","journal-title":"Hepatology"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41591-019-0379-5","article-title":"Platelet GPIb\u03b1 Is a Mediator and Potential Interventional Target for NASH and Subsequent Liver Cancer","volume":"25","author":"Malehmir","year":"2019","journal-title":"Nat. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1038\/ncomms3823","article-title":"Fate Tracing Reveals Hepatic Stellate Cells as Dominant Contributors to Liver Fibrosis Independent of Its Aetiology","volume":"4","author":"Mederacke","year":"2013","journal-title":"Nat. Commun."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41586-022-05289-6","article-title":"Opposing Roles of Hepatic Stellate Cell Subpopulations in Hepatocarcinogenesis","volume":"610","author":"Filliol","year":"2022","journal-title":"Nature"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1053\/j.gastro.2017.06.007","article-title":"Identification of an Immune-Specific Class of Hepatocellular Carcinoma, Based on Molecular Features","volume":"153","author":"Sia","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"33293","DOI":"10.1074\/jbc.R100016200","article-title":"The Serpins Are an Expanding Superfamily of Structurally Similar but Functionally Diverse Proteins. Evolution, Mechanism of Inhibition, Novel Functions, and a Revised Nomenclature","volume":"276","author":"Silverman","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1002\/1097-0142(197710)40:4<1621::AID-CNCR2820400435>3.0.CO;2-I","article-title":"Radioimmunoassay for Tumor Antigen of Human Cervical Squamous Cell Carcinoma","volume":"40","author":"Kato","year":"1977","journal-title":"Cancer"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/002215540004800112","article-title":"Co-Expression of the Squamous Cell Carcinoma Antigens 1 and 2 in Normal Adult Human Tissues and Squamous Cell Carcinomas","volume":"48","author":"Cataltepe","year":"2000","journal-title":"J. Histochem. Cytochem."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1038\/bjc.2014.246","article-title":"SERPINB3 Is Associated with TGF-\u03b21 and Cytoplasmic \u03b2-Catenin Expression in Hepatocellular Carcinomas with Poor Prognosis","volume":"110","author":"Turato","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/liv.15049","article-title":"The Protease-Inhibitor SerpinB3 as a Critical Modulator of the Stem-like Subset in Human Cholangiocarcinoma","volume":"42","author":"Correnti","year":"2022","journal-title":"Liver Int."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.ejca.2011.06.004","article-title":"Over-Expression of SERPINB3 in Hepatoblastoma: A Possible Insight into the Genesis of This Tumour?","volume":"48","author":"Turato","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/S1665-2681(19)30974-3","article-title":"Role of SERPINB3 in Hepatocellular Carcinoma","volume":"13","author":"Pontisso","year":"2014","journal-title":"Ann. Hepatol."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Tolomeo, A.M., Quarta, S., Biasiolo, A., Ruvoletto, M., Pozzobon, M., De Lazzari, G., Malvicini, R., Turato, C., Arrigoni, G., and Pontisso, P. (2021). Engineered EVs for Oxidative Stress Protection. Pharmaceuticals, 14.","DOI":"10.3390\/ph14080703"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1054\/bjoc.2000.1683","article-title":"Squamous Cell Carcinoma Antigen Suppresses Radiation-Induced Cell Death","volume":"84","author":"Murakami","year":"2001","journal-title":"Br. J. Cancer"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1083\/jcb.200508064","article-title":"Serpin Squamous Cell Carcinoma Antigen Inhibits UV-Induced Apoptosis via Suppression of c-JUN NH2-Terminal Kinase","volume":"172","author":"Katagiri","year":"2006","journal-title":"J. Cell Biol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.18632\/oncotarget.1411","article-title":"SERPINB3 Protects from Oxidative Damage by Chemotherapeutics through Inhibition of Mitochondrial Respiratory Complex I","volume":"5","author":"Ciscato","year":"2013","journal-title":"Oncotarget"},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Turato, C., Fornari, F., Pollutri, D., Fassan, M., Quarta, S., Villano, G., Ruvoletto, M., Bolondi, L., Gramantieri, L., and Pontisso, P. (2019). MiR-122 Targets SerpinB3 and Is Involved in Sorafenib Resistance in Hepatocellular Carcinoma. J. Clin. Med., 8.","DOI":"10.3390\/jcm8020171"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/path.2708","article-title":"SERPINB3 Induces Epithelial-Mesenchymal Transition","volume":"221","author":"Quarta","year":"2010","journal-title":"J. Pathol."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Chen, L., Shi, V., Wang, S., Sun, L., Freeman, R.N., Yang, J., Inkman, M.J., Ghosh, S., Ruiz, F., and Jayachandran, K. (2023). SCCA1\/SERPINB3 Suppresses Anti-Tumor Immunity and Blunts Therapy-Induced T Cell Responses via STAT-Dependent Chemokine Production. J. Clin. Investig.","DOI":"10.1172\/JCI163841"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1038\/labinvest.2010.55","article-title":"SERPINB3 Modulates TGF-\u03b2 Expression in Chronic Liver Disease","volume":"90","author":"Turato","year":"2010","journal-title":"Lab. Investig."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1258\/ebm.2011.010229","article-title":"Increased Antiprotease Activity of the SERPINB3 Polymorphic Variant SCCA-PD","volume":"236","author":"Turato","year":"2011","journal-title":"Exp. Biol. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/labinvest.2011.1","article-title":"Overexpression of SERPIN B3 Promotes Epithelial Proliferation and Lung Fibrosis in Mice","volume":"91","author":"Lunardi","year":"2011","journal-title":"Lab. Investig."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/thx.2007.088583","article-title":"Overexpression of Squamous Cell Carcinoma Antigen in Idiopathic Pulmonary Fibrosis: Clinicopathological Correlations","volume":"63","author":"Calabrese","year":"2008","journal-title":"Thorax"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"15732","DOI":"10.18632\/oncotarget.14997","article-title":"SerpinB3 Upregulates the Cyclooxygenase-2 \/ \u03b2-Catenin Positive Loop in Colorectal Cancer","volume":"8","author":"Terrin","year":"2017","journal-title":"Oncotarget"},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Quarta, S., Cappon, A., Turato, C., Ruvoletto, M., Cannito, S., Villano, G., Biasiolo, A., Maggi, M., Protopapa, F., and Bertazza, L. (2023). SerpinB3 Upregulates Low-Density Lipoprotein Receptor-Related Protein (LRP) Family Members, Leading to Wnt Signaling Activation and Increased Cell Survival and Invasiveness. Biology, 12.","DOI":"10.3390\/biology12060771"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"910526","DOI":"10.3389\/fimmu.2022.910526","article-title":"SerpinB3 as a Pro-Inflammatory Mediator in the Progression of Experimental Non-Alcoholic Fatty Liver Disease","volume":"13","author":"Novo","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.molcel.2019.07.028","article-title":"Landscape of Intercellular Crosstalk in Healthy and NASH Liver Revealed by Single-Cell Secretome Gene Analysis","volume":"75","author":"Xiong","year":"2019","journal-title":"Mol. Cell"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1111\/cas.13986","article-title":"Squamous Cell Carcinoma Antigen 1 Is Associated to Poor Prognosis in Esophageal Cancer through Immune Surveillance Impairment and Reduced Chemosensitivity","volume":"110","author":"Turato","year":"2019","journal-title":"Cancer Sci."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.3389\/fimmu.2018.02081","article-title":"SERPINB3 Delays Glomerulonephritis and Attenuates the Lupus-Like Disease in Lupus Murine Models by Inducing a More Tolerogenic Immune Phenotype","volume":"9","author":"Gatto","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10555-007-9055-1","article-title":"Hypoxia in Cancer: Significance and Impact on Clinical Outcome","volume":"26","author":"Vaupel","year":"2007","journal-title":"Cancer Metastasis Rev."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s00109-007-0281-3","article-title":"Hypoxia and Cancer","volume":"85","author":"Chiche","year":"2007","journal-title":"J. Mol. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.molcel.2010.09.022","article-title":"Hypoxia-Inducible Factors and the Response to Hypoxic Stress","volume":"40","author":"Majmundar","year":"2010","journal-title":"Mol. Cell"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/cdd.2008.21","article-title":"The Role of Hypoxia-Inducible Factors in Tumorigenesis","volume":"15","author":"Rankin","year":"2008","journal-title":"Cell Death Differ."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.semradonc.2008.12.002","article-title":"Cancer Stem Cells, Hypoxia and Metastasis","volume":"19","author":"Hill","year":"2009","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jcmgh.2021.10.002","article-title":"Hepatocyte-Specific Deletion of HIF2\u03b1 Prevents NASH-Related Liver Carcinogenesis by Decreasing Cancer Cell Proliferation","volume":"13","author":"Foglia","year":"2022","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1093\/carcin\/bgn216","article-title":"Redox Mechanisms Switch on Hypoxia-Dependent Epithelial-Mesenchymal Transition in Cancer Cells","volume":"29","author":"Cannito","year":"2008","journal-title":"Carcinogenesis"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jhep.2014.08.025","article-title":"Hypoxia Inducible Factors in Liver Disease and Hepatocellular Carcinoma: Current Understanding and Future Directions","volume":"61","author":"Wilson","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.trecan.2016.10.016","article-title":"Hypoxia-Inducible Factors: Master Regulators of Cancer Progression","volume":"2","author":"Schito","year":"2016","journal-title":"Trends Cancer"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"46691","DOI":"10.18632\/oncotarget.17358","article-title":"Hypoxia Inducible Factors in Hepatocellular Carcinoma","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"20130676","DOI":"10.1259\/bjr.20130676","article-title":"Defining Normoxia, Physoxia and Hypoxia in Tumours\u2014Implications for Treatment Response","volume":"87","author":"McKeown","year":"2014","journal-title":"Br. J. Radiol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"409272","DOI":"10.1155\/2014\/409272","article-title":"The Role of Hypoxia Inducible Factor-1 in Hepatocellular Carcinoma","volume":"2014","author":"Luo","year":"2014","journal-title":"BioMed. Res. Int."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1002\/hep.23597","article-title":"Roles of Hypoxia-Inducible Factor-1\u03b1 (HIF-1\u03b1) Versus HIF-2\u03b1 in the Survival of Hepatocellular Tumor Spheroids","volume":"51","author":"Menrad","year":"2010","journal-title":"Hepatology"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1349-7006.2011.02177.x","article-title":"Downregulating Hypoxia-Inducible Factor-2\u03b1 Improves the Efficacy of Doxorubicin in the Treatment of Hepatocellular Carcinoma","volume":"103","author":"He","year":"2012","journal-title":"Cancer Sci."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/hep.26188","article-title":"Hypoxia Inducible Factor 2 alpha Inhibits Hepatocellular Carcinoma Growth through the Transcription Factor Dimerization Partner 3\/ E2F Transcription Factor 1-Dependent Apoptotic Pathway","volume":"57","author":"Sun","year":"2013","journal-title":"Hepatology"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.cellsig.2014.01.026","article-title":"Upregulation of HIF-2\u03b1 Induced by Sorafenib Contributes to the Resistance by Activating the TGF-\u03b1\/EGFR Pathway in Hepatocellular Carcinoma Cells","volume":"26","author":"Zhao","year":"2014","journal-title":"Cell. Signal."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"34571","DOI":"10.18632\/oncotarget.8952","article-title":"Downregulation and Pro-Apoptotic Effect of Hypoxia-Inducible Factor 2 Alpha in Hepatocellular Carcinoma","volume":"7","author":"Yang","year":"2016","journal-title":"Oncotarget"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"10839","DOI":"10.18632\/aging.102488","article-title":"HIF-2\u03b1 Upregulation Mediated by Hypoxia Promotes NAFLD-HCC Progression by Activating Lipid Synthesis via the PI3K-AKT-mTOR Pathway","volume":"11","author":"Chen","year":"2019","journal-title":"Aging"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.18632\/oncotarget.2943","article-title":"Hypoxia Up-Regulates SERPINB3 through HIF-2\u03b1 in Human Liver Cancer Cells","volume":"6","author":"Cannito","year":"2015","journal-title":"Oncotarget"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"17701","DOI":"10.1038\/srep17701","article-title":"SerpinB3 and Yap Interplay Increases Myc Oncogenic Activity","volume":"5","author":"Turato","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Cannito, S., Foglia, B., Villano, G., Turato, C., Delgado, T.C., Morello, E., Pin, F., Novo, E., Napione, L., and Quarta, S. (2019). SerpinB3 Differently Up-Regulates Hypoxia Inducible Factors-1\u03b1 and -2\u03b1 in Hepatocellular Carcinoma: Mechanisms Revealing Novel Potential Therapeutic Targets. Cancers, 11.","DOI":"10.3390\/cancers11121933"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/14\/3629\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:12:34Z","timestamp":1760127154000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/14\/3629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,15]]},"references-count":148,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["cancers15143629"],"URL":"https:\/\/doi.org\/10.3390\/cancers15143629","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,15]]}}}